Fisfalen M E, Soliman M, Okamoto Y, Soltani K, DeGroot L J
Department of Medicine, University of Chicago, Illinois 60637, USA.
J Clin Endocrinol Metab. 1995 May;80(5):1597-604. doi: 10.1210/jcem.80.5.7745006.
We studied the immune responses of 33 patients with autoimmune thyroid disease (AITD; including 17 with Hashimoto's thyroiditis and 16 with Graves' disease), 5 patients with non-AITD, 12 control subjects (CS), and 2 subjects with a family history of autoimmunity to the main thyroid antigens. These antigens included thyroid peroxidase (TPO), thyroglobulin (Tg), TSH receptor (TSH-R), and 13 overlapping TPO peptides. T-cell lines (TCL) were isolated from peripheral blood mononuclear cells (PBMC) after incubation with TPO, Tg, or a protein derivative of tuberculin (PPD). PBMC and TCL were used in a 3- to 5-day microproliferation assay. Peripheral lymphocytes from most AITD patients responded with a stimulation index of 3 or more to TPO, Tg, and/or TSH-R (60-88%) as well as to two or more TPO peptides. Lymphocytes from 3 of 5 patients with non-AITD and 2 subjects with a family history of autoimmunity were also reactive to thyroid antigens. TPO TCL showed a high proliferative response to TPO and its peptides, whereas Tg TCL were less reactive and PPD TCL were nonreactive to these antigens. Six of the 13 peptides tested produced highly significant stimulation in PBMC (CS, 0-17%; AITD, 60-92%) and TPO TCL (73-91%). The amino acid sequences of these putative epitopes were located in TPO regions 100-119, 211-223, 261-275, 420-434, 625-644, and 882-901. These results demonstrate T-cell responses to the main thyroid antigens, including TPO, Tg, and TSH-R, and confirm the heterogeneity of TPO T-cell epitopes in patients with AITD. Amino acid residues 100-119, 420-434, 625-644, and 882-901 are the most common sites recognized by TPO TCL, indicating that they may be immunogenic epitopes in AITD.
我们研究了33例自身免疫性甲状腺疾病(AITD;包括17例桥本甲状腺炎和16例格雷夫斯病)患者、5例非AITD患者、12名对照受试者(CS)以及2名有自身免疫家族史的受试者对主要甲状腺抗原的免疫反应。这些抗原包括甲状腺过氧化物酶(TPO)、甲状腺球蛋白(Tg)、促甲状腺激素受体(TSH-R)以及13种重叠的TPO肽段。在与TPO、Tg或结核菌素蛋白衍生物(PPD)孵育后,从外周血单个核细胞(PBMC)中分离出T细胞系(TCL)。PBMC和TCL用于3至5天的微量增殖试验。大多数AITD患者的外周淋巴细胞对TPO、Tg和/或TSH-R(60 - 88%)以及两种或更多TPO肽段的刺激指数达到3或更高。5例非AITD患者中的3例以及2名有自身免疫家族史的受试者的淋巴细胞也对甲状腺抗原产生反应。TPO TCL对TPO及其肽段表现出高增殖反应,而Tg TCL反应较弱,PPD TCL对这些抗原无反应。所测试的13种肽段中有6种在PBMC(CS,0 - 17%;AITD,60 - 92%)和TPO TCL(73 - 91%)中产生了高度显著的刺激。这些推定表位的氨基酸序列位于TPO的100 - 119、211 - 223、261 - 275、420 - 434、625 - 644和882 - 901区域。这些结果证明了T细胞对主要甲状腺抗原(包括TPO、Tg和TSH-R)的反应,并证实了AITD患者中TPO T细胞表位的异质性。氨基酸残基100 - 119、420 - 434、625 - 644和882 - 901是TPO TCL识别的最常见位点,表明它们可能是AITD中的免疫原性表位。